首页> 外文期刊>BMC Cardiovascular Disorders >Serum neuron-specific enolase as predictor of outcome in comatose cardiac-arrest survivors: a prospective cohort study
【24h】

Serum neuron-specific enolase as predictor of outcome in comatose cardiac-arrest survivors: a prospective cohort study

机译:血清神经元特异性烯醇化酶可预测昏迷性心脏骤停幸存者预后:一项前瞻性队列研究

获取原文
           

摘要

Background The prediction of neurological outcome in comatose patients after cardiac arrest has major ethical and socioeconomic implications. The purpose of this study was to assess the capability of serum neuron-specific enolase (NSE), a biomarker of hypoxic brain damage, to predict death or vegetative state in comatose cardiac-arrest survivors. Methods We conducted a prospective observational cohort study in one university hospital and one general hospital Intensive Care Unit (ICU). All consecutive patients who suffered cardiac arrest and were subsequently admitted from June 2007 to February 2009 were considered for inclusion in the study. Patients who died or awoke within the first 48 hours of admission were excluded from the analysis. Patients were followed for 3 months or until death after cardiopulmonary resuscitation. The Cerebral Performance Categories scale (CPC) was used as the outcome measure; a CPC of 4-5 was regarded as a poor outcome, and a CPC of 1-3 a good outcome. Measurement of serum NSE was performed at 24 h and at 72 h after the time of cardiac arrest using an enzyme immunoassay. Clinicians were blinded to NSE results. Results Ninety-seven patients were included. All patients were actively supported during the first days following cardiac arrest. Sixty-five patients (67%) underwent cooling after resuscitation. At 3 months 72 (74%) patients had a poor outcome (CPC 4-5) and 25 (26%) a good outcome (CPC 1-3). The median and Interquartile Range [IQR] levels of NSE at 24 h and at 72 h were significantly higher in patients with poor outcomes: NSE at 24 h: 59.4 ng/mL [37-106] versus 28.8 ng/mL [18-41] (p 97 ng/mL) with 100% positive predictive value of poor outcome. Nevertheless, for decisions concerning the continuation of treatment in this setting, we emphasize that an approach based on a combination of SSEPs, NSE and clinical EEG would be more accurate for identifying patients with a poor neurological outcome.
机译:背景心脏骤停后昏迷患者神经系统预后的预测具有重大的伦理和社会经济意义。这项研究的目的是评估缺氧性脑损伤的生物标志物血清神经元特异性烯醇化酶(NSE)预测昏迷性心脏骤停幸存者死亡或营养状态的能力。方法我们在一家大学医院和一家综合医院重症监护室(ICU)进行了一项前瞻性观察队列研究。所有自2007年6月至2009年2月均因心脏骤停而随后入院的连续患者被考虑纳入研究。入院前48小时内死亡或醒来的患者被排除在分析之外。随访患者3个月,或直到心肺复苏后死亡。脑功能分类量表(CPC)被用作结果测量。每次点击费用的4-5被认为是较差的结果,而每次点击费用1-3则被认为是良好的结果。使用酶免疫法在心脏骤停后的24小时和72小时进行血清NSE的测量。临床医生对NSE的结果视而不见。结果纳入了97例患者。在心脏骤停后的头几天,所有患者均得到积极支持。复苏后有65名患者(67%)接受了降温。在3个月时,有72位(74%)患者的预后较差(CPC 4-5),而25位(26%)的患者预后良好(CPC 1-3)。结果差的患者在24 h和72 h时NSE的中位数和四分位数范围[IQR]水平显着更高:24 h NSE:59.4 ng / mL [37-106]比28.8 ng / mL [18-41] ](p 97 ng / mL)和100%不良预后的阳性预测值。但是,对于有关在这种情况下继续治疗的决定,我们强调基于SSEP,NSE和临床EEG的组合的方法将更准确地识别出神经系统预后不良的患者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号